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A b s T r A C T
background: in clinical practice, type 1 and type 2 diabetic 
patients are sometimes difficult to distinguish. Type 1 
diabetes has an immune-mediated pathogenesis, resulting 
in a loss of insulin-secreting b-cells. Type 2 diabetes 
mellitus is characterised by a relative insulin insufficiency, 
without the presence of an autoimmune aetiology, initially 
due to insulin resistance and later also accompanied by 
defective insulin release. latent autoimmune diabetes of 
the adult (lAdA) is a subgroup of diabetes, somewhere 
on the borderland between type 1 and type 2 diabetes. 
lAdA is characterised by a late-age onset and relatively mild 
progression, but with unmistakable signs of autoimmunity, 
such as the presence of the autoimmune antibodies anti-
gAd65, anti-insulin antibodies, or anti-ia-2ab.
objective: To establish the prevalence of anti-gAd in 
a diabetic outpatient clinic of a dutch, non-university, 
teaching hospital and to describe these patients clinical and 
laboratory features, especially of the metabolic syndrome. 
Methods: we evaluated gAd65 antibodies and other 
parameters in 244 selected diabetic patients, who had been 
on oral therapy for at least three months before becoming 
insulin-dependent. 
results: Twenty-six patients (11.6%) were positive for 
gAd65 antibodies. These patients had a significantly 
lower bMi (27.8 ± 4.5 vs 31.1 ± 4.9; p <0.01); less often 
cerebrovascular accidents (19.2 vs 34.9%; p<0.01) and a 
higher hdl cholesterol (1.73 ± 0.53 vs 1.21 ± 0.38; p<0.05). 
in contrast, anti-gAd patients had a significantly higher 
prevalence of hypothyroidism (23.0 vs 6.6%; p<0.05).
Conclusion: Anti-gAd-positive patients represent a sizable 
proportion of type 2 diabetes in a second-line outpatient 
clinic, and they are characterised by lower parameters of 
the metabolic syndrome, but higher prevalence of other 
autoimmune phenomena such as hypothyroidism.
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i N T r o d u C T i o N
Classification of adult-onset diabetes mellitus (DM) into 
type 1 or 2 based on the clinical presentation may be 
difficult.1,2 Diagnosis of the main forms of diabetes 
depends on clinical judgment based mainly on the age 
of the subject and the severity of insulin deficiency at 
presentation, as well as the presence or absence of features 
of the metabolic syndrome. In the WHO classification of 
1998, an aetiological classification was chosen to subgroup 
the different types of diabetes.3 
Type 1 DM refers to a loss of insulin-secreting b-cells of the 
islets of Langerhans, in most cases by immune-mediated 
pathogenic mechanisms highlighted by the presence of 
islet cell autoantibodies and by an altered frequency of 
immune-regulated genes in the HLA region. In European 
patients with type 1 DM 95% have positive glutamic acid 
decarboxylase (GAD65) and/or IA2 antibodies to antigens 
of the islets of Langerhans; especially the finding of GAD65 
antibodies seems a quite stable finding after the age of 
10 to 15 years in autoimmune diabetes.4,5 Type 2 DM is 
characterised by a relative insulin insufficiency, without 
the presence of an autoimmune aetiology, initially due to 
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insulin resistance and later also accompanied by defective 
insulin release due to amyloid deposition in the pancreas. 
Both of these major diabetes types include different stages 
ranging from not requiring insulin to diabetes that does 
require insulin for control or survival. It is recognised 
that the type 2 DM process does not invariably lead to 
insulin dependency nor, on the other hand, is total insulin 
deficiency exclusively classified as type 1 DM.
Furthermore a subgroup of diabetic patients can be 
distinguished with evidence of autoimmunity but who 
clinically resemble type 2 DM at diagnosis. Autoantibody 
positivity together with subsequent development of insulin 
deficiency led to the introduction of the eponym latent 
autoimmune diabetes in adults (LADA) for this subgroup,6 
type 1.5 diabetes,7 or latent type 1 DM.8 However, there is 
still an ongoing debate as to whether these names cover 
the same subgroup of diabetes.9 LADA exits somewhere 
on the borderland between type 1 and type 2 diabetes, and 
exemplifies the difficulties we have in telling type 1 from 
type 2.10 Because of its slow progression to insulin therapy, 
early identification of anti-GAD-positive patients could 
lead to implementation of preventive measures to protect 
residual b-cell function. 
There is no consensus regarding diagnostic criteria of 
LADA. The grounds for designating LADA as a distinct 
aetiological entity are insubstantial. Several studies have 
used different criteria especially concerning the age of 
onset of diabetes and the duration of the insulin-free 
period.11-13 Mainly because of these different criteria the 
prevalence of LADA patients varies in published studies, 
from 2.8%14 to 22.3%.15 In a large study, not restricted to 
hospital outpatients as the United Kingdom Prospective 
Diabetes Study (UKPDS) is, a prevalence of 10% was 
found.16
The aim of the present study was to establish the prevalence 
of anti-GAD in a diabetic outpatient clinic of a Dutch, non-
university, teaching hospital and to describe these patients 
clinical and laboratory features of the metabolic syndrome. 
p A T i E N T s  A N d  M E T h o d s
patients
During a four-month period, we studied consecutive 
patients with DM type 2 who visited the outpatient clinic 
of the Jeroen Bosch Hospital, where 1600 patients with 
diabetes are monitored annually. Each year we see 200 new 
diabetic patients, 70% of whom start on insulin therapy. 
Inclusion criteria were DM type 2 (nonketotic diabetes 
without insulin treatment over at least three months of 
observation), who were treated with insulin at the start 
of the study or treated with maximal oral therapy and 
supposed to start on insulin in the next month.
Exclusion criteria were malignancy, autoimmune diseases, 
known abnormal thyroid function at the time of the study, 
use of NSAIDS or acetylsalicylic acid, or infections in the 
previous two weeks before the start of the study. These 
exclusion criteria were adopted because of further cytokine 
studies in the LADA population. From all the patients, 
blood tests were taken, including fasting glucose and lipids, 
HbA1c, thyroid function and microalbuminuria (abnormal: 
>30 mg albumin/24 hours). They all underwent a standard 
physical examination for late diabetic complications and 
cardiovascular risk factors and diseases. Hypertension 
was defined as use of antihypertensive drugs or blood 
pressure >140/80 mmHg. Peripheral neuropathy was 
scored as positive when vibration sense by a 128 Hz 
vibration fork at both hallux was absent, combined with 
a disturbed 10 g Semmes-Weinstein monofilament test 
and absent ankle reflexes. Macroangiopathy was present 
when a patient had coronary disease, defined as one or 
more coronary events, PTCA or CABG, or when a patient 
had proven cerebrovascular damage. Peripheral vascular 
disease was defined as symptoms of claudication and 
absence of foot pulses and/or a toe pressure <30 mmHg or 
proven peripheral vascular disease, either by radiography 
or vascular intervention. The diagnosis of retinopathy was 
based on fundoscopy after pharmacological mydriasis 
by an ophthalmologist. Hypothyroidism was defined as 
treatment with thyrax or a TSH concentration >6 mU/l and 
an fT4 level <13 umol/l. 
determination of autoantibodies
Ia-2a antibodies and GAD65 antibodies were determined 
by radiobinding assays with in vitro translated recombinant 
human 35S-GAD65. GAD65-ab were expressed as relative 
indices, using one positive standard serum from one type 1 
diabetic subject and two negative control sera from healthy 
subjects in each assay, and an upper level of normal of 
0.035 U (mean +3SD from the indices observed in healthy 
individuals). The diagnostic sensitivity of the GAD65-
antibody assays was 85%, the analytic specificity 100%.17 
Informed consent was obtained from all patients.
s T A T i s T i C  A N A l y s i s
Data will be given as mean ± standard deviation (SD) or as 
median and range. Student t-test was used for continuous 
variables, x2 test for dichotomous variables. Level of 
significance was p value <0.05.
r E s u l T s
A total of 407 type 2 DM patients visited the outpatient 
clinic during the study period. Of these patients, 183 were 
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excluded from the study because of refusal (1 patient), 
missing variables (6) or because of the following exclusion 
criteria: malignancy (10), autoimmune disease (31), 
acetylsalicylic acid use (84), NSAID use (49), and known 
abnormal thyroid function (2).
Of the remaining 224 patients, 26 had positive GAD65 
antibodies (11.6%). The median anti-GAD level was 0.55 U 
(range 0.12 to 2.3 U). Of the 26 GAD65-positive patients, 
five had positive Ia-2A antibodies (19.2%). In the other 198 
(anti-GAD-negative) type 2 diabetic patients there were 
no positive Ia-2A antibodies. Demographic characteristics 
of the anti-GAD population in comparison with the anti-
GAD-negative type 2 diabetic population are mentioned 
in table 1. There was a female predominance in the anti-
GAD population (73%) compared with the non-anti-GAD 
population (57%). The body mass index in the non-anti-
GAD population was significantly higher than in the anti-
GAD population (p<0.01). The prevalence of hypertension 
was similar in both groups, as were macroangiopathic 
complications, with the exception of cerebrovascular 
accidents, which were seen more frequently in the non-anti-
GAD type 2 diabetic population (p<0.01). The prevalence 
of microvascular diabetic complications did not differ 
between the two groups. In 23% of the anti-GAD patients 
there was a hypothyroidism, compared with 7% in the 
non-anti-GAD population (p<0.05). The laboratory results 
of the two diabetic populations are shown in table 2. HbA1c 
was similar in both groups. Total cholesterol results were 
comparable in the two groups, but in the anti-GAD patients 
the high-density lipoprotein (HDL) cholesterol value was 
significantly higher (p<0.05): the triglycerides were lower 
in the anti-GAD patients, but this was not statistically 
significant.
d i s C u s s i o N
The main finding of our study is that the prevalence of anti-
GAD-positive patients in a Dutch non-university, teaching 
hospital was 11.6 % of the total type 2 diabetic population 
and that in the anti-GAD population less features of 
the metabolic syndrome were present. The prevalence 
found is comparable with other studies, for instance the 
UKPDS.16 If only type 2 diabetic patients were included 
with at least a six-month insulin-free period at diagnosis, 
recommended by Fourlanos et al. for diagnosing LADA, 
the prevalence would have been almost the same: 12.7% 
(23/181).13 However, our study results have some limitations 
concerning the selection of the study population. No type 
2 diabetic patients on only oral diabetic medication were 
included. It is possible that we overestimated the prevalence 
of anti-GAD-positive patients in our population because of 
the exclusion criteria, especially the exclusion of patients 
who were on acetylsalicylic acid: 84 of the 183 excluded 
patients (45.9%). Patients usually take acetylsalicylic acid 
because of macrovascular complications, a result of the 
metabolic syndrome. In this subgroup the prevalence of 
anti-GAD is supposed to be small. On the other hand, 
if LADA is a slow-developing autoimmune diabetes, by 
excluding patients with autoimmune diseases, we may have 
underestimated the prevalence. In line with this hypothesis 
is the high prevalence (23%) of hypothyroidism found 
Table 1. Demographic characteristics of the anti-GAD-positive population in comparison with the anti-GAD-negative 
type 2 diabetic population
variable Anti-gAd positive 
(n=26)
Anti-gAd negative 
(n=198)
p
Sex (% female) 73 57 ns
Age (years) (mean ± SD) 59.3 ± 16.3 63.6 ± 12.8 ns
BMI (kg/m2) (mean ± SD) 27.8 ± 4.5 31.1 ± 4.9 0.006
Time to starting insulin after DM diagnosis  
(mean ± SD) (months)
13.2 ± 9.1 14.7 ± 8.0 ns
Smoker (%) 23.1 (6/26) 24.7 (47/190) ns
Neuropathy (%) 42.3 (11/26) 59.2 (103/174) ns
Retinopathy (%) 26.9 (7/26) 34.7 (65/188) ns
Microalbuminuria (%) 32.0 (8/25) 29.4 (40/136) ns
Hypertension (%) 46.2 (12/26) 43.5 (84/193) ns
Cerebrovascular incident (%) 19.2 (5/26) 34.9 (55/166) <0.01
Peripheral vascular disease (%) 30.8 (8/26) 27.1 (52/192) ns
Coronary damage (%) 11.5 (3/26) 19.7 (38/193) ns
Hypothyroidism (%) 23 (6/26) 6.6 (13/198) <0.05
gAd = glutamic acid decarboxylase; bMi = body mass index; dM = diabetes mellitus; ns = not significant.
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in our anti-GAD population. The association between 
autoimmune thyroid disease and type 1 diabetes has been 
reported in the past.18,19 Recent studies have also found 
a higher prevalence of thyroid autoantibodies in adult 
diabetic patients with positive GAD65 antibodies.17,20 The 
fact that 73% of the anti-GAD population is female is in 
accordance with an autoimmune pathogenesis of LADA. 
In older studies, the presence of islet autoantibodies 
was also associated with female sex.8,21 In the study by 
Gambelunghe et al. the same high female prevalence in 
the anti-GAD patient group was found.17
The patients with anti-GAD in this study also had a better 
lipid profile and lower body mass index (BMI), compared 
with the type 2 diabetic patients without anti-GAD.22 There 
was a tendency of less cardiovascular events in the anti-
GAD population, which only reached statistical significance 
in the prevalence of cerebrovascular accidents.22 The 
prevalence of hypertension did not differ between the 
two groups, as was found in several other studies.22,23 
Concerning the long-term diabetic complications there was 
no difference in prevalence of retinopathy, neuropathy and 
microalbuminuria.
These phenotypic differences of anti-GAD-positive patients 
compared with type 2 DM are more subtle and there seems 
to be less evidence of the metabolic syndrome. Probably 
this anti-GAD population of diabetic patients are type 1 
diabetics diagnosed at an earlier phase or there is a true 
difference in the progression rate of insulin deficiency.
Hosszufalusi showed similar clinical characteristics and 
a high prevalence of predisposing risk alleles (HLA-
DQB1*0302, -DR4, -DR3, -DR3/DR4) and risk haplotypes 
(DR4-DQB1*0302) in patients with LADA and adult-onset 
type 1 diabetes with rapid progression.24 But he also 
showed that patients with LADA often had single positive 
islet cell-specific autoantibodies, in contrast to those with 
adult-onset type 1 diabetes with rapid progression. Others 
found a decreased frequency of the protective HLA type 
0602 in the type 1 DM population.25 Preliminary data of a 
prospective study on 22 newly diagnosed diabetic patients 
showed after a median follow-up of 2.3 years an unchanged 
fasting and glucagon stimulated C-peptide concentration 
in 11 LADA patients compared with 11 type 1 diabetic 
patients.26 These facts pointed to a difference in the rate of 
deterioration of b-cell function between the two groups.
Assuming that LADA is a slow progressive type 1 form 
of diabetes, prevention of b-cell destruction should be 
attempted.27 A pilot trial in 1996 comparing insulin and 
sulphonylureas in LADA patients showed that insulin-
treated patients maintained higher B-cell function 
than those treated with sulphonylureas.28 Early use of 
insulin could preserve endogenous insulin secretion and 
probably delay or prevent the decline of B-cell function. 
Cabrera-Rode et al. showed in 2002 that exclusion of 
sulphonylureas in treatment of slowly progressing type 
1 DM patients partially decreases specific autoimmunity 
against endocrine pancreatic cells and improves metabolic 
control.29 This suggests that initial insulin monotherapy is 
a good choice for the treatment of LADA patients, but this 
hypothesis has, beside the study by Kobayashi,28 never been 
proved. The UKPDS confirmed that patients with LADA 
are more likely to progress to insulin, but it also showed 
that after ten years, or indeed at any point in between, those 
initially randomised to diet or sulphonylurea therapy did 
not differ in any respect from those initially randomised 
to insulin.30 Another possibility is medication with anti-
inflammatory properties, as shown by the reduction of 
cytokines such as tumour necrosis factor. Rosiglitazone 
has been shown to possess such effects in vitro and reduced 
the incidence of autoimmune diabetes in NOD mice.31 
More and prospective studies are needed to confirm the 
superiority of this suggested treatment regime and to 
implement it in daily care. 
Table 2. Laboratory results of the anti-GAD-positive population in comparison with the anti-GAD negative type 2 
diabetic population
variable Anti-gAd positive 
(n=26)
Anti-gAd negative 
(n=198)
p
Positive GAD65 antibodies (N) 26 0 -
Anti-GAD65 level (U) (median/range) 0.55 (0.12 - 2.3) - -
Positive IA-2Ab (%) 19.2% 0 -
IA-2Ab level (U) (median/range) 0.001 (-0.6 - 2.62) - -
HbA1c (mmol/l) (mean ± SD) 8.3 ± 1.6 8.5 ± 1.4 ns
Total cholesterol (mmol/l) (mean ± SD) 5.4 ± 1.06 5.2 ± 0.9 ns
HDL cholesterol (mmol/l) (mean ± SD) 1.73 ± 0.53 1.21 ± 0.38 <0.05
LDL cholesterol (mmol/l) (mean ± SD) 2.88 ± 1.16 3.08 ± 0.8 ns
Triglycerides (mmol/l) 1.63 ± 1.88 2.07 ± 1.52 ns
gAd = glutamic acid decarboxylase; hdl = high-density lipoprotein; ldl = low-density lipoprotein; ns = not significant.
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In daily practice this means that we could measure GAD 
antibodies in early type 2 diabetic patients (lower BMI, 
better lipid profile, hypothyreoidism, women). In case 
of positive antibodies, an earlier start of insulin is often 
needed. This anti-GAD-positive diabetic population with 
slow progression to insulin therapy compared with type 
1 diabetes gives the opportunity of testing therapeutic 
modalities to protect the b-cell.
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